-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Advances in molecular diagnostics have allowed us to identify a new type of pediatric gliomas-infantile hemispheric gliomas-which appear in the cerebral hemisphere and are often confirmed as malignant by histology (World Health Organization Grade III or IV)
Diagnosis of these gliomas containing ALK, ROS1, NTRK1/2/3, and MET receptor tyrosine kinase rearrangements.
Manage blood vessels
Recently, researchers published an article in the New England Journal , reporting a case of a 3-year-old boy who was sent to the emergency department due to vomiting, excessive sleepiness, and exotropia that lasted for 2 to 3 weeks and was in a coma
After the New England Journal of intracranial hemorrhage occurred again, further intervention was considered futile
ALK diffuse to the immune response of high-grade astrocytoma diffuse to ALK immune response of high-grade astrocytic tumors immune RNA sequencing revealed SPECC1L-ALK fusion RNA sequencing revealed SPECC1L-ALK fusion
Taking into account the patient's clinical condition and the discovery of ALK fusion, based on good data on the intracranial response of adult non-small cell lung cancer, doctors chose loratinib as a treatment method
According to data of good adult non-small cell lung cancer brain response, doctors chose Lola imatinib as a treatment based on good data intracranial reaction adult non-small cell lung cancer, the doctors chose Lola imatinib as a treatment dose of 95 mg per square meter of body surface area, once a day dose is 95 mg per square meter of body surface area, once a day
Response to loratinib
The response to loratinib The response to loratinibSurprisingly, after the treatment, the patient began to recover.
The patient began to recover.
The proliferation index of the tumor is significantly decreased .
The paralysis was resolved within one week after resuming treatment.
cholesterol
ALK inhibitors penetrate the central nervous system through biochemical means, such as loratinib, which can affect the primary tumors of the central nervous system with target lesions.
Original source:
Original source:Aditi Bagchi et al.
Aditi Bagchi et al.
Leave a message here
